Biocon Receives Supplemental US FDA Approval for Yesintek Prefilled Autoinjectors
Biocon's US subsidiary has received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in multiple strengths. Originally approved in November 2024, Yesintek treats moderate to severe plaque psoriasis, active psoriatic arthritis in patients aged six and older, and moderate to severe Crohn's disease and ulcerative colitis in adults. The new delivery format aims to provide tailored treatment options across care settings. Biocon highlighted this approval as enhancing its immunology portfolio and commitment to affordable medicines.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 44/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–65/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 18 Aug, 03:54 am. Other outlets followed.
- 1businessstandard18 Aug, 03:54 amBiocon announces USFDA approval for Yesintek single-dose prefilled autoinjector
- 2businessstandard18 Aug, 04:26 amBiocon gets supplemental US FDA nod for Yesintek prefilled autoinjector
Who's involved
Institutions and figures named across source coverage.
Story context
- Category
- Business
- Location
- United States
- Sources analysed
- 2
- Last analysed
- 18 Aug 2026
- Key entities
- BioconFood and Drug AdministrationUnited StatesPsoriatic arthritisPsoriasisUlcerative colitisAutoimmune diseasePediatricsAutoinjectorCrohn's diseaseProteinSubsidiary